Sugi Predict

Sugi Predict / Compounds / SCHEMBL5857541

SCHEMBL5857541

SCHEMBL5857541

COc1ccc(C(=O)NCC(C)=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.65
▸ RAB9A P51151 4/20 0.65
▸ CA1 P00915 2/20 0.62
▸ CA2 P00918 2/20 0.62
▸ PKM P14618 1/20 0.61
▸ PLK1 P53350 1/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ TP53 P04637 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ CTDSP1 Q9GZU7 1/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ EPHX2 P34913 1/20 0.55
▸ NR1H4 Q96RI1 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ SLC6A9 P48067 1/20 0.55
▸ SLC6A5 Q9Y345 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13203130 0.87 KDM4E (0.53) NPC1RAB9ACA1CA2SMN1; SMN2
SCHEMBL15595417 0.86 KDM4E (0.70) NPC1RAB9ACA1CA2PKM
SCHEMBL1193504 0.86 NPC1 (0.65) NPC1RAB9ACA1CA2PKM
SCHEMBL2796671 0.86 ALDH1A1 (0.67) NPC1RAB9ACA1CA2PKM
SCHEMBL10672288 0.85 NPC1 (0.56) NPC1RAB9ACA1CA2PKM
SCHEMBL8598019 0.85 NPC1 (0.69) NPC1RAB9ACA1CA2PKM
SCHEMBL23329985 0.85 PKM (0.60) NPC1RAB9ACA1CA2PKM
SCHEMBL28968582 0.83 NPC1 (0.58) NPC1RAB9ACA1CA2PKM
SCHEMBL16685001 0.83 NPC1 (0.83) NPC1RAB9ACA1CA2PKM
SCHEMBL11668774 0.83 MMP1 (0.68) NPC1RAB9ACA1CA2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105993-B Synthesis method of chiral pyrroloimidazole compound 大连理工大学 2023-03-10 — — CN disclosed
EP-3971176-A1 AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE Hinova Pharmaceuticals Inc. (CN) 2022-03-23 — — EP disclosed
CN-114105993-A Synthesis method of chiral pyrroloimidazole compound 大连理工大学 2022-03-01 — — CN disclosed
EP-3957633-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2022-02-23 — — EP disclosed
WO-2020233512-A1 AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE 成都海创药业有限公司 (CN) 2020-11-26 — — WO disclosed
WO-2020211822-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF 成都海创药业有限公司 2020-10-22 — — WO disclosed
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 — — EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 — — US disclosed
EP-2694472-A2 SULFONAMIDE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2014-02-12 — — EP disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 — — US disclosed
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 — — US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 — — US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 — — US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 — — EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 — — US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 — — US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 — — US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 — — US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 — — US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB NPC1 32/4885RAB9A 3996/4885CA1 4428/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE NPC1 40/4885RAB9A 3631/4885CA1 4516/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC NPC1 63/4885RAB9A 3492/4885CA1 4533/4885
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 NPC1 2770/4885RAB9A 3305/4885CA1 1931/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC NPC1 63/4885RAB9A 3492/4885CA1 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.